Similar articles for PMID: 19387424

Year	Number of Results
2001	1
2002	3
2003	3
2004	7
2005	9
2006	16
2007	18
2008	15
2009	19
2010	14
2011	16
2012	16
2013	15
2014	18
2015	24
2016	18
2017	9
2018	7
2019	12
2020	12
2021	11
2022	10
2023	5
2024	0

1

A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).

Ramoz N, Boni C, Downing AM, Close SL, Peters SL, Prokop AM, Allen AJ, Hamon M, Purper-Ouakil D, Gorwood P. Ramoz N, et al. Neuropsychopharmacology. 2009 Aug;34(9):2135-42. doi: 10.1038/npp.2009.39. Epub 2009 Apr 22. Neuropsychopharmacology. 2009. PMID: 19387424 Clinical Trial.

2

Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children.

Yang L, Qian Q, Liu L, Li H, Faraone SV, Wang Y. Yang L, et al. J Neural Transm (Vienna). 2013 Jul;120(7):1127-33. doi: 10.1007/s00702-012-0955-z. Epub 2012 Dec 25. J Neural Transm (Vienna). 2013. PMID: 23266789

3

Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.

Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, Rubin RL, Pigott TA, Sarkis EH, Fox BK. Durell TM, et al. J Clin Psychopharmacol. 2013 Feb;33(1):45-54. doi: 10.1097/JCP.0b013e31827d8a23. J Clin Psychopharmacol. 2013. PMID: 23277268 Clinical Trial.

4

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.

Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group. Dell'Agnello G, et al. Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28. Eur Neuropsychopharmacol. 2009. PMID: 19716683 Clinical Trial.

5

CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.

Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. Michelson D, et al. J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):242-51. doi: 10.1097/01.chi.0000246056.83791.b6. J Am Acad Child Adolesc Psychiatry. 2007. PMID: 17242628

6

Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.

Ercan ES, Akyol Ardic U, Kabukcu Basay B, Ercan E, Basay O. Ercan ES, et al. Atten Defic Hyperact Disord. 2013 Dec;5(4):377-85. doi: 10.1007/s12402-013-0111-0. Epub 2013 Jun 5. Atten Defic Hyperact Disord. 2013. PMID: 23737214

7

A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.

Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, Pamulapati S, Buitelaar JK, Hoekstra PJ. Harfterkamp M, et al. J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):733-41. doi: 10.1016/j.jaac.2012.04.011. Epub 2012 May 25. J Am Acad Child Adolesc Psychiatry. 2012. PMID: 22721596 Clinical Trial.

8

Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.

Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM. Adler LA, et al. Clin Ther. 2012 Feb;34(2):363-73. doi: 10.1016/j.clinthera.2011.12.015. Epub 2012 Jan 27. Clin Ther. 2012. PMID: 22285724

9

Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.

Angyal N, Horvath EZ, Tarnok Z, Richman MJ, Bognar E, Lakatos K, Sasvari-Szekely M, Nemoda Z. Angyal N, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):122-128. doi: 10.1016/j.pnpbp.2018.01.013. Epub 2018 Feb 20. Prog Neuropsychopharmacol Biol Psychiatry. 2018. PMID: 29374517

10

A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K; SUNBEAM Study Group. Prasad S, et al. Curr Med Res Opin. 2007 Feb;23(2):379-94. doi: 10.1185/030079906X167309. Curr Med Res Opin. 2007. PMID: 17288692 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

239 results

Results by year